Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.5.0.2
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Jul. 31, 2016
Jul. 31, 2015
Jul. 31, 2014
Revenues:      
Clinical laboratory services $ 70,915 $ 63,414 $ 58,689
Product revenues 30,337 31,690 32,850
Royalty and license fee income 1,521 2,495 4,408
Total revenues 102,773 97,599 95,947
Operating costs, expenses and legal settlements, net:      
Cost of clinical laboratory services 42,859 39,589 38,948
Cost of product revenues 14,331 15,183 15,320
Research and development 3,524 3,350 3,141
Selling, general, and administrative 43,586 41,069 41,801
Provision for uncollectible accounts receivable 2,336 2,284 3,063
Legal fee expense 6,384 8,788 6,954
Legal settlements, net (57,250) (11,458) (3,100)
Total costs, expenses and legal settlements, net 55,770 98,805 106,127
Operating income (loss) 47,003 (1,206) (10,180)
Other income (expense):      
Interest (136) (245) (208)
Other 122 95 194
Foreign exchange (loss) gain (474) (936) 289
Income (loss) before income taxes 46,515 (2,292) (9,905)
Benefit (provision) for income taxes (1,229) 7 (72)
Net income (loss) $ 45,286 $ (2,285) $ (9,977)
Net income (loss) per common share:      
Basic (in Dollars per share) $ 0.98 $ (0.05) $ (0.23)
Diluted (in Dollars per share) $ 0.97 $ (0.05) $ (0.23)
Weighted average common shares outstanding:      
Basic (in Shares) 46,153 45,355 42,561
Diluted (in Shares) 46,602 45,355 42,561